Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

Nat. Rev. Rheumatol. doi: /nrrheum

Advertisements

Figure 1 Role of innate lymphoid cells (ILCs) in steady state,

Figure 3 The adaptive and maladaptive energy matrices

Figure 3 Connexins in cartilage

Figure 5 Involvement of B cells in SLE

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 4 Host damage from infection-related inflammatory

Figure 2 Functional model of enthesitis

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Factors underlying metabolic alterations in osteoarthritis

Figure 1 Induction of immune tolerance

Figure 2 Risk factors for sarcopenia

Figure 3 Microanatomical changes in enthesitis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Main functions of IL-1

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Schematic comparison of expected

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 7 Defects in apoptosis

Figure 3 Nucleic acid sensors in SLE

Figure 1 Location of HLA variants known to be associated

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 3 Cell-surface markers for NP cell differentiation

Figure 6 Lack of IRF5 causes a reduction in neutrophil influx

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 5 The role of Ly6Chi and Ly6Clo monocytes

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Figure 1 Simplified EULAR and GRAPPA

Figure 1 Evolution of multiple sclerosis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Emerging hallmarks of T cells in rheumatoid arthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 Biospecimen handling pipeline

Figure 1 The current model of the pathogenesis of SLE

Figure 1 Reproductive health in patients with rheumatic diseases

Figure 1 Principles for the diagnosis and management of osteoarthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Embryonic origins of tissue-resident macrophages

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Chronic inflammation and DNA damage in people with SLE

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 2 Phenotypes of osteoarthritis

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Figure 1 Extrinsic and intrinsic pathways of apoptosis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The role of macrophages in RA

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Nat. Rev. Rheumatol. doi: /nrrheum

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.179 Figure 3 Multi-layer model of pathogenic events leading to the development of MAS in the context of rheumatic diseases Figure 3 | Multi-layer model of pathogenic events leading to the development of MAS in the context of rheumatic diseases. Genetic factors and the inflammatory milieu created by the underlying rheumatic disease act synergistically to reach the threshold for macrophage activation syndrome (MAS) in the presence of an infectious trigger. Grom, A. A. et al. (2016) Macrophage activation syndrome in the era of biologic therapy Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.179